BC
BCRX.US BioCryst Pharmaceuticals Inc
- Market cap
- USD 1.96B
- P/E
- -
- P/B
- 56.59x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BCRX.US undervalued?
Graham numberThe Graham number of BioCryst Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BioCryst Pharmaceuticals Inc fundamental analysis
No fundamental analysis for BioCryst Pharmaceuticals Inc yet.
BioCryst Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton …
Full company profileBioCryst Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BioCryst Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 26.4M | 25.2M | 20.7M | 48.8M | 17.8M | 157M | 271M | 331M | 451M | 875M | 740M |
| Gross Profit | 23.7M | 23.5M | 20.2M | 44.7M | 16.1M | 150M | 264M | 327M | 438M | 856M | -205M |
| Operating Income | -48.6M | -57.4M | -94.2M | -99.5M | -175M | -178M | -148M | -104M | -2.54M | 341M | -733M |
| EBITDA | -48.2M | -56.5M | -90.4M | -96.3M | -168M | -122M | -144M | -116M | 12.8M | 348M | -735M |
| Net Income | -55.1M | -65.8M | -101M | -109M | -183M | -184M | -247M | -227M | -88.9M | 264M | -807M |
| EPS | -0.75 | -0.78 | -0.98 | -0.94 | -1.09 | -1.03 | -1.33 | -1.18 | -0.43 | 1.21 | -3.02 |
| Balance Sheet | |||||||||||
| Total Assets | 89.8M | 178M | 147M | 175M | 335M | 588M | 550M | 517M | 490M | 514M | 591M |
| Total Liabilities | 88.3M | 94.5M | 97.6M | 137M | 354M | 695M | 845M | 972M | 966M | 633M | 988M |
| Shareholders' Equity | -566M | -632M | -732M | 38.3M | -19.3M | -107M | -295M | -456M | -476M | -119M | -397M |
| Cash & Short-term Investments | 63.6M | 156M | 127M | 136M | 300M | 508M | 424M | 389M | 321M | 275M | 375M |
| Total Debt | 53.7M | 54.7M | 61.8M | 84.7M | 151M | 593M | 741M | 825M | 841M | 439M | 828M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -53.4M | -41.1M | -92.6M | -89.6M | -137M | -142M | -162M | -95.1M | -52.0M | 330M | 100M |
| Capital Expenditure | 5.28M | 328K | 366K | 343K | 514K | 2.39M | 1.35M | 2.17M | 1.12M | 2.47M | 1.13M |
| Free Cash Flow | -58.7M | -41.5M | -92.9M | -89.9M | -138M | -145M | -163M | -97.3M | -53.1M | 327M | 99.1M |
| Ratios | |||||||||||
| ROE | - | - | - | -284.7% | - | - | - | - | - | - | - |
| ROA | -61.4% | -36.9% | -69.0% | -62.1% | -54.6% | -31.3% | -44.9% | -43.8% | -18.1% | 51.3% | -136.6% |
| Net Profit Margin | -209.3% | -261.2% | -490.3% | -223.0% | -1,026.4% | -117.1% | -91.2% | -68.4% | -19.7% | 30.2% | -109.1% |
| Debt to Equity | - | - | - | 2.21x | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
BioCryst Pharmaceuticals Inc dividends
BioCryst Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Who owns BioCryst Pharmaceuticals Inc
- Insiders 3.35%
- Institutions 96.65%
- Public & others 0.00%
- Shares outstanding 257M
- Free float 224M
Top funds holding BCRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 8.12M | 3.16% | +0.40% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 7.39M | 2.87% | +2.69% | Oct 2026 |
| iShares Russell 2000 ETF | 5.63M | 2.19% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 2.88M | 1.12% | -1.51% | Sep 2026 |
| abrdn Healthcare Investors | 2.62M | 1.02% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 2.54M | 0.99% | +0.16% | Aug 2026 |
| abrdn Healthcare Opportunities | 2.32M | 0.90% | 0.00% | Sep 2026 |
| Candriam Eqs L Biotech C USD Cap | 2.22M | 0.86% | -2.88% | Apr 2026 |
| iShares Russell 2000 Growth ETF | 2.10M | 0.82% | -0.38% | Oct 2026 |
| Janus Henderson Hrzn Biotec E2 USD | 2.09M | 0.81% | +12.59% | Jun 2026 |
| iShares Biotechnology ETF | 1.71M | 0.66% | -0.19% | Oct 2026 |
| Vanguard Strategic Equity Inv | 1.70M | 0.66% | -17.50% | Sep 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 1.60M | 0.62% | -4.34% | Sep 2026 |
| abrdn Life Sciences Investors | 1.37M | 0.53% | +13.72% | Sep 2026 |
| CREF Total Global Stock Account R3 | 1.34M | 0.52% | -5.57% | Aug 2026 |
| Vanguard Russell 2000 ETF | 1.30M | 0.51% | -2.63% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 1.26M | 0.49% | +0.24% | Oct 2026 |
| Vanguard Explorer Inv | 1.24M | 0.48% | -7.18% | Sep 2026 |
| Invesco Biotechnology & Genome ETF | 1.18M | 0.46% | 0.00% | Oct 2026 |
| Nuveen Quant Small Cap Equity R6 | 1.12M | 0.44% | 0.00% | Aug 2026 |
Top institutions holding BCRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 23.9M | 9.29% | +5.48% | Jun 2026 |
| RA Capital Management, LLC | 15.8M | 6.15% | 0.00% | Jun 2026 |
| State Street Corp | 15.2M | 5.90% | +24.43% | Jun 2026 |
| Deerfield Management Co | 15.1M | 5.87% | +0.39% | Jun 2026 |
| Vanguard Capital Management, LLC | 11.4M | 4.42% | +2.05% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 11.1M | 4.33% | -0.94% | Jun 2026 |
| TCG Crossover Management, LLC | 11.0M | 4.28% | 0.00% | Jun 2026 |
| Perceptive Advisors LLC | 10.3M | 4.01% | +38.67% | Jun 2026 |
| Jupiter Topco LLC | 9.54M | 3.71% | 0.00% | Jun 2026 |
| Vestal Point Capital LP | 8.30M | 3.23% | +18.15% | Jun 2026 |
| Two Sigma Investments LLC | 6.78M | 2.63% | +5.99% | Jun 2026 |
| Geode Capital Management, LLC | 6.25M | 2.43% | +8.05% | Jun 2026 |
| Aberdeen Group PLC | 5.31M | 2.06% | +5.36% | Jun 2026 |
| UBS Group AG | 5.08M | 1.97% | +2.72% | Jun 2026 |
| Bank of America Corp | 4.80M | 1.87% | -5.70% | Jun 2026 |
| The Goldman Sachs Group Inc | 4.48M | 1.74% | +90.93% | Jun 2026 |
| Frazier Life Sciences Management, L.P. | 4.01M | 1.56% | 0.00% | Jun 2026 |
| Nuveen, LLC | 4.01M | 1.56% | +4.92% | Jun 2026 |
| Nantahala Capital Management, LLC | 3.80M | 1.48% | +91.32% | Jun 2026 |
| Millennium Management LLC | 3.39M | 1.32% | +1,708.39% | Jun 2026 |
BioCryst Pharmaceuticals Inc company profile
- Company name
- BioCryst Pharmaceuticals Inc
- Ticker
- BCRX.US
- Exchange
- USA Stocks
- Listed since
- Mar 3, 1994
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 435
- Fiscal year end
- December
- Address
- 4505 Emperor Boulevard, Durham, NC, United States, 27703
- Phone
- 919 859 1302
- Website
- biocryst.com
About BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
BioCryst Pharmaceuticals Inc management
10- Mr. Charles K. GayerCEO, President & Director · born 1971
- Mr. Babar GhiasCFO & Head of Corporate Development · born 1979
- Ms. Alane P. BarnesSenior VP, Chief Legal Officer & Corporate Secretary · born 1966
- Mr. John RueschChief Technical Operations Officer
- Dr. David W. Jenkins M.A., Ph.D.Chief Scientific Officer
- Nick WilderManager of Investor Relations
- Ms. Stephanie AngeliniChief People Officer & Communications Officer
- Dr. William P. Sheridan MBBSChief Development Officer · born 1955
- Dr. Yarlagadda S. Babu Ph.D.Chief Discovery Officer · born 1953
- Ms. Jinky Ang RosselliChief Data Innovation Officer